News on Medial

Novo Nordisk wants to boost India GCC capacity, but no plans for production unit

Livemint · 3m

Danish drug manufacturer Novo Nordisk plans to expand its collaborations with existing partners in India to increase its operations in the country. The company, known for its diabetes and weight-loss drugs, has been facing a shortage of supply globally. In order to meet the demand, Novo will expand its manufacturing capacities at existing production sites rather than setting up a new hub. Novo also plans to add 1,300 new job roles to its Indian centre by 2026, with 700 hires expected this year. India's Global Capability Centres (GCCs) have become a preferred route for multinational corporations (MNCs) to establish their operations due to cost advantages and supportive government policies. India currently has over 1,600 GCCs, with the number expected to reach 2,100 by 2028. GCCs are predicted to contribute approximately 3.5% to India's GDP by 2030.